| 吉西他滨或长春瑞滨联合顺铂治疗晚期非小细胞肺癌的系统评价 |
| 投稿时间：2012-02-13 修订日期：2012-03-01 点此下载全文 |
| 引用本文：何志高,鲍思蔚,翟晓波.吉西他滨或长春瑞滨联合顺铂治疗晚期非小细胞肺癌的系统评价[J].药学实践杂志,2012,30(2):131~136 |
| 摘要点击次数: 1351 |
| 全文下载次数: 350 |
|
| 基金项目:"浦东新区卫生系统医学领先人才培训项目"(PWRd2007-12)资助. |
|
| 中文摘要:目的 利用Meta分析评价吉西他滨、长春瑞滨联合顺铂治疗晚期非小细胞肺癌的有效性与安全性。方法 检索Pubmed数据库和CHKD数据库,纳入随机对照试验,用专用软件Review Manager Version4.2.2进行系统评价。结果 共有7个英文期刊文献研究1 561例患者,10个中文期刊文献研究864例患者纳入系统评价。英文期刊文献Meta分析结果显示吉西他滨+顺铂方案与长春瑞滨+顺铂方案在总缓解率上无区别,在一年生存率上吉西他滨+顺铂方案方案优于长春瑞滨+顺铂方案,中文期刊文献Meta分析结果显示两套方案在总缓解率和一年生存率上均无显著性差异。关于毒性反应方面的报道,中英文期刊文献Meta分析结果一致,吉西他滨+顺铂方案中性粒细胞减少发生率低于长春瑞滨+顺铂方案,血小板减少发生率高于长春瑞滨+顺铂方案,恶心呕吐发生率差异无统计学意义。结论 中英文期刊文献在评价吉西他滨、长春瑞滨联合顺铂治疗晚期非小细胞肺癌的有效性上有区别。应重视提高中文期刊随机对照研究文献的质量,同时在晚期非小细胞肺癌治疗过程中,应结合患者具体情况,选择对患者生活质量影响较小的方案。 |
| 中文关键词:晚期非小细胞肺癌 化学治疗 吉西他滨 长春瑞滨 顺铂 Meta分析 |
| |
| Meta-analysis of gemcitabine versus vinorelbine combined with cisplatin in treatment of advanced non-small cell lung cancer |
|
|
| Abstract:Objective To compare and evaluate the effectiveness and security of gemcitabine versus vinorelbine combined with cisplatin in treatment of advanced non-small cell lung cancer by Meta-analysis. Methods PubMed database and CHKD database were searched, included in randomized controlled trials. Special software Review Manager Version 4.2.2 was used to systematic reviews. Results Seven studies of English journals involving 1 561 patients and ten studies of Chinese journals involving 864 patients were included. There was no difference in the overall response from gemcitabine versus vinorelbine in combination with cisplatin by Meta-analysis of English and Chinese journals. But the project of gemcitabine+cisplatin was superior to vinorelbine+cisplatin in 1-year survival rate of English journals and there was no difference in 1-year survival rate by Meta-analysis of Chinese journals. Both English and Chinese journals showed the same reports of toxicity. The incidence rate of neutropenia was higher in vinorelbine+cisplatin, and the thrombocytopenia was higher in gemcitabine + cisplatin, nausea and vomiting and nervous system response were no significant difference between two groups. Conclusions The effectiveness of gemcitabine versus vinorelbine combined with cisplatin of advanced non-small cell lung cancer was different. Improving the quality of RCT in Chinese journals was very important. |
| keywords:advanced non-small cell lung cancer chemotherapy gemcitabine vinorelbine cisplatin Meta-znalysis |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
| 关闭 |
|
|
|
